InMed Pharmaceuticals (INM) Institutional Ownership $2.06 -0.58 (-21.97%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$2.20 +0.14 (+6.60%) As of 03/28/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for InMed Pharmaceuticals (NASDAQ:INM)CurrentInstitutional OwnershipPercentage20.12%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$3.29M Get INM Insider Trade Alerts Want to know when executives and insiders are buying or selling InMed Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data INM Institutional Buying and Selling by Quarter Remove Ads InMed Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025 AdvisorShares Investments LLC38,460$177K0.0%-94.8%5.342% 2/13/2024 Armistice Capital LLC205,968$86K0.0%N/A3.916% 11/14/2022 Armistice Capital LLC90,000$593K0.0%-90.6%9.605% 5/17/2022Empery Asset Management LP61,741$58K0.3%N/A0.437% 8/17/2021 Armistice Capital LLC890,000$2.83M0.1%+278.7%9.954% 8/12/2021 Penserra Capital Management LLC19,912$49K0.0%N/A0.223% 5/21/2021 Citadel Advisors LLC17,211$57K0.0%N/A0.214% 5/18/2021 Citadel Advisors LLC17,211$57K0.0%N/A0.214% 5/17/2021 Armistice Capital LLC235,000$776K0.0%N/A2.919% (Data available from 1/1/2016 forward)Remove Ads INM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INM shares? During the previous two years, the following institutional investors and hedge funds held shares of InMed Pharmaceuticals shares: AdvisorShares Investments LLC ($177K), Armistice Capital LLC ($86K).Learn more on INM's institutional investors. What percentage of InMed Pharmaceuticals stock is owned by institutional investors? 20.12% of InMed Pharmaceuticals stock is owned by institutional investors. Learn more on INM's institutional investor holdings. Which institutional investors have been buying InMed Pharmaceuticals stock? The following institutional investors have purchased InMed Pharmaceuticals stock in the last 24 months: Armistice Capital LLC ($205.97K). How much institutional buying is happening at InMed Pharmaceuticals? Institutional investors have bought a total of 205,968 shares in the last 24 months. This purchase volume represents approximately $1.71M in transactions. Which InMed Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold InMed Pharmaceuticals stock in the last 24 months: AdvisorShares Investments LLC ($694.84K). How much institutional selling is happening at InMed Pharmaceuticals? Institutional investors have sold a total of 694,836 shares in the last 24 months. This volume of shares sold represents approximately $3.29M in transactions. Related Companies IXHL Major Shareholders CTXR Major Shareholders IMNN Major Shareholders FLGC Major Shareholders BMRA Major Shareholders ATHA Major Shareholders APRE Major Shareholders TRIB Major Shareholders MBRX Major Shareholders BCDA Major Shareholders This page (NASDAQ:INM) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
